List of Excipients in Branded Drug PARICALCITOL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
West-Ward Pharmaceuticals Corp	PARICALCITOL	paricalcitol	0143-9625	ALCOHOL
West-Ward Pharmaceuticals Corp	PARICALCITOL	paricalcitol	0143-9625	SORBITOL
West-Ward Pharmaceuticals Corp	PARICALCITOL	paricalcitol	0143-9625	WATER
Hospira Inc	PARICALCITOL	paricalcitol	0409-1008	ALCOHOL

Generic Drugs Containing PARICALCITOL

Company	Ingredient	NDC	Excipient
Banner Pharmacaps	paricalcitol	10888-5001	ALCOHOL
Banner Pharmacaps	paricalcitol	10888-5001	BUTYLATED HYDROXYTOLUENE
Banner Pharmacaps	paricalcitol	10888-5001	FERROSOFERRIC OXIDE
Banner Pharmacaps	paricalcitol	10888-5001	GELATIN

What are the Most Frequently-Used Excipients in PARICALCITOL?

# Of NDCs	Excipient
21	ALCOHOL
5	AMMONIA
4	BUTYL ALCOHOL
15	BUTYLATED HYDROXYTOLUENE

Paricalcitol Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Paricalcitol is a mature vitamin D receptor agonist used to prevent and treat secondary hyperparathyroidism associated with chronic kidney disease. Its commercial opportunity is concentrated in generic oral capsules, injectable products used in dialysis settings, hospital supply reliability, and differentiated formulations rather than new-molecule exclusivity.

The most attractive excipient strategies are:

1. Reducing ethanol and propylene glycol exposure in parenteral products.
2. Improving oral dose uniformity at 1 mcg, 2 mcg and 4 mcg strengths.
3. Developing preservative-free or ready-to-use injectable presentations.
4. Creating capsule formulations with fewer allergens and colorants.
5. Optimizing packaging and low-volume delivery for dialysis providers.
6. Supporting combination or co-packaged renal-mineral-bone-disorder products.

What is paricalcitol and how is it administered?

Paricalcitol is a synthetic analog of calcitriol that selectively activates the vitamin D receptor. It is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease, including patients receiving hemodialysis or peritoneal dialysis. The product is administered orally as capsules and intravenously as an injection. [1]

Product type	Typical strengths or concentration	Primary setting	Excipient priorities
Oral capsule	1 mcg, 2 mcg, 4 mcg	Outpatient and dialysis patients	Dose uniformity, capsule compatibility, colorant reduction
Intravenous injection	2 mcg/mL and 5 mcg/mL	Hemodialysis and institutional care	Solubilization, tolerability, sterility, container compatibility
Generic capsule	Strengths generally aligned with reference product	Retail, specialty and dialysis channels	Bioequivalence, manufacturing cost and supply continuity
Generic injection	Reference-equivalent concentration	Hospitals and dialysis clinics	Ready-to-use delivery, low extractables and reliable fill-finish

Paricalcitol is highly lipophilic. The oral product therefore uses a lipid-containing vehicle, while the injectable product uses organic cosolvents to maintain solubility in an aqueous parenteral presentation. [1]

What excipients are used in paricalcitol products?

Oral capsule excipients

The Zemplar capsule label identifies a lipid and cosolvent system that includes medium-chain triglycerides, ethanol and propylene glycol. The capsule shell contains gelatin and glycerin, with titanium dioxide and colorants used depending on capsule strength. [1]

The formulation logic is commercially important:

• Medium-chain triglycerides provide a lipid vehicle for the poorly water-soluble active ingredient.
• Ethanol and propylene glycol support dissolution and content uniformity.
• Gelatin and glycerin provide the softgel shell structure.
• Titanium dioxide and colorants differentiate strengths and support product identification.

For generic manufacturers, the highest-risk oral formulation attributes are not usually the individual excipients. They are the interaction between the active ingredient and the lipid vehicle, the migration of solvents into the capsule shell, and dose uniformity at microgram-level loading.

Injectable excipients

The injectable product uses ethanol, propylene glycol and water for injection. The organic solvents maintain paricalcitol in solution at the labeled concentration. [1]

This creates several development and commercial considerations:

• Ethanol and propylene glycol can affect injection-site tolerability.
• The solvent system can interact with elastomeric closures and plastic components.
• Long-term stability must address precipitation, adsorption and leachables.
• Dialysis use favors products that are easy to handle and do not require additional dilution.
• Low-volume vials can reduce waste but increase the importance of fill-volume control.

A formulation that reduces solvent content while maintaining clarity and chemical stability could create a meaningful product distinction, particularly for high-volume institutional use.

Which excipient strategies are most commercially attractive?

1. Low-solvent injectable paricalcitol

The strongest near-term opportunity is a parenteral formulation that reduces ethanol and propylene glycol while maintaining the required concentration and shelf life.

Potential technologies include:

• Mixed cosolvent systems.
• Cyclodextrin complexation.
• Surfactant-assisted solubilization.
• Lipid-based nanoemulsions.
• Solubilizing polymers.
• Alternative vial or cartridge presentations.
• Concentrated formulations designed for controlled dilution.

Any replacement must preserve chemical stability and avoid unacceptable hemolysis, hypersensitivity, precipitation or infusion-related effects. Because the product is administered to patients with substantial renal impairment, excipient exposure should be assessed carefully even when the dose volume is small.

The commercial value is highest if the formulation can support a 505(b)(2) product with a clinically meaningful administration or tolerability advantage. A formulation that only changes the excipient list without improving labeling, handling or patient outcomes may face limited pricing power.

2. Preservative-free and ready-to-use formats

Dialysis centers value predictable preparation, reduced handling and lower medication waste. A preservative-free, ready-to-use vial or prefilled syringe could compete on operational efficiency rather than active-ingredient differentiation.

Key design parameters include:

• Single-dose packaging.
• Low residual volume.
• Compatibility with standard dialysis workflows.
• Clear visual inspection.
• Short preparation time.
• Stable storage under routine pharmacy conditions.
• Container closure integrity through the labeled shelf life.

The strongest target is a presentation that reduces compounding steps or prevents vial overfill waste. The value proposition should be quantified in terms of dose preparation time, discarded product and medication-error risk.

3. Oral softgel systems with improved dose uniformity

Paricalcitol capsules contain microgram quantities of active ingredient. A small absolute assay error can produce a material percentage deviation. A high-performance lipid formulation can improve dispersion before encapsulation and reduce unit-to-unit variability.

Potential approaches include:

• Pre-concentrated active solutions in medium-chain triglycerides.
• Alternative lipid excipients with higher solubilization capacity.
• Controlled mixing and recirculation during manufacture.
• In-process near-infrared testing.
• Improved encapsulation controls.
• Lower-oxygen manufacturing and packaging.

These improvements may have greater value as a manufacturing platform than as a consumer-facing product claim. They can reduce batch failures, improve yield and support reliable generic supply.

4. Gelatin-free and colorant-reduced capsules

Some patients and purchasers prefer non-gelatin dosage forms or products with fewer synthetic colorants. A vegetarian capsule, HPMC-based shell or colorless softgel could create niche differentiation.

The technical issues are material:

• Oil migration through the shell.
• Shell brittleness or leakage.
• Water activity control.
• Oxygen permeability.
• Seal integrity.
• Stability of the paricalcitol solution inside the shell.

This strategy is commercially more plausible for oral solid-dose expansion than for a major premium product. It may support hospital formulary, specialty pharmacy or international market access requirements.

5. Modified-release or food-effect management

A modified-release product could seek to reduce peak concentrations, simplify dosing or improve adherence. The commercial case is weaker because paricalcitol is generally administered under a dosing regimen managed by laboratory monitoring, and the existing capsule product is established.

A formulation sponsor would need a clear clinical or pharmacokinetic benefit. A modified-release product without improved parathyroid hormone control, reduced monitoring burden or fewer adverse effects would have limited differentiation.

What regulatory pathway applies to paricalcitol excipient innovation?

ANDA pathway

A conventional generic capsule or injection generally proceeds through an abbreviated new drug application if it demonstrates pharmaceutical equivalence and bioequivalence to the reference listed drug. FDA evaluates active ingredient, strength, dosage form, route of administration and performance requirements. [2]

Excipient differences are possible, but the generic product must remain equivalent in critical performance characteristics. Injectable products face particular scrutiny regarding sterility, particulate matter, container closure, extractables and leachables.

505(b)(2) pathway

A novel paricalcitol formulation may qualify for a 505(b)(2) application when the sponsor relies partly on FDA findings for an approved product but introduces a meaningful change in formulation, dosage form, route, delivery system or use. [3]

Potential 505(b)(2) concepts include:

• Reduced-solvent injection.
• Prefilled syringe.
• Alternative delivery device.
• New oral delivery system.
• Modified-release formulation.
• New concentration or administration method.

The regulatory strategy depends on whether the change requires new clinical studies. Excipient substitution alone may not support meaningful exclusivity unless it produces a recognized clinical or administration benefit.

FDA excipient expectations

FDA review will focus on safety, quality and performance. Important documentation includes:

• Excipient specifications.
• Supplier qualification.
• Residual solvent controls.
• Elemental impurity assessment.
• Microbial limits and sterility controls.
• Compatibility with the active ingredient.
• Photostability and temperature stability.
• Container closure data.
• Extractables and leachables.
• Risk assessment for nitrosamines and other process-related impurities where relevant.

Inactive ingredients are recorded in FDA product labeling and the Inactive Ingredient Database, which can support precedent analysis but does not eliminate the need for product-specific justification. [4]

What patents protect paricalcitol formulations?

The original compound and product protection for Zemplar are mature. The core commercial position has moved from innovator exclusivity to generic competition and manufacturing differentiation.

Potentially relevant intellectual-property categories include:

IP category	Commercial relevance
Paricalcitol compound claims	Core protection; generally expired or no longer a primary barrier
Oral capsule composition	May cover solvent ratios, lipid vehicles, capsule shell or stability characteristics
Injectable composition	May cover solvent systems, concentrations, pH, stability or packaging
Method-of-use claims	May cover CKD populations, dosing regimens or treatment methods
Manufacturing methods	May cover mixing, encapsulation, purification or fill-finish controls
Device claims	May cover prefilled syringes, cartridges or dialysis administration systems

A current Orange Book and patent-register review is required for product-specific conclusions. FDA’s Orange Book identifies listed patents and regulatory exclusivity associated with approved products, but it does not capture every potentially relevant manufacturing, trade-secret or foreign patent right. [5]

For a new excipient platform, trade secrets may be more valuable than patent claims if the differentiation depends on process controls, solvent handling, mixing order, oxygen management or capsule encapsulation parameters.

When does paricalcitol lose exclusivity?

Paricalcitol has already entered the mature generic phase in the United States. Generic capsules and injections are available, and the principal market barriers are regulatory approval, manufacturing capability, quality performance and contracting rather than basic molecule exclusivity.

Exclusivity issue	Current commercial implication
New-molecule exclusivity	Expired
Core compound patent protection	Mature and not generally the principal barrier
Orange Book listed formulation patents	Must be checked product by product
Paragraph IV risk	Relevant if a newly listed patent covers a commercial formulation or use
Pediatric exclusivity	No central commercial barrier identified for current generic strategy
Biosimilar exclusivity	Not applicable

What is the Paragraph IV risk for paricalcitol?

A Paragraph IV certification may be relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable or not infringed. The risk is generally lower for a mature product with expired core protection, but it can remain relevant for later-listed formulation or method-of-use patents. [2]

For paricalcitol, the highest-value Paragraph IV targets would be:

• Injectable solvent systems.
• Specific concentrations.
• Ready-to-use presentations.
• Narrow treatment methods.
• Patents covering capsule composition or stability.

The commercial value of a Paragraph IV challenge depends on the remaining market size, the scope of the asserted claims and the expected timing of launch. A formulation patent with narrow claims may be designed around rather than litigated.

Which companies are challenging or competing with paricalcitol?

The competitive field includes the originator manufacturer, generic pharmaceutical companies and alternative vitamin D receptor agonists.

Direct paricalcitol competitors

Direct competition includes generic versions of oral and injectable paricalcitol. Manufacturers compete on:

• Wholesale acquisition cost.
• Contract pricing.
• FDA shortage performance.
• Dialysis-provider supply agreements.
• Manufacturing location.
• Fill-finish capacity.
• Product availability in multiple strengths.
• Packaging and handling efficiency.

Public data do not reliably separate paricalcitol revenue by manufacturer because products are often reported within broader generic or renal portfolios.

Therapeutic competitors

Paricalcitol competes with other agents used in secondary hyperparathyroidism, including:

• Calcitriol.
• Doxercalciferol.
• Etelcalcetide.
• Cinacalcet.
• Evocalcet in markets where approved.

These products differ in mechanism, route, monitoring requirements, cost and use across dialysis populations. Calcimimetics can reduce parathyroid hormone without relying on the same vitamin D receptor agonist pathway, while vitamin D analogs may be selected based on calcium and phosphate management considerations. [6]

What manufacturing and IP barriers affect commercial entry?

The most important barriers are technical rather than molecule-specific.

Oral manufacturing barriers

• Uniform distribution of a microgram-level active ingredient.
• Stable dissolution in a lipid vehicle.
• Prevention of capsule leakage.
• Control of shell moisture.
• Protection from light and oxygen.
• Consistent color and capsule identification.
• Scale-up of softgel encapsulation.

Injectable manufacturing barriers

• Maintaining a clear solution.
• Preventing precipitation during storage and dilution.
• Controlling ethanol and propylene glycol levels.
• Sterile filtration and aseptic filling.
• Managing vial adsorption and extractables.
• Demonstrating container closure integrity.
• Controlling particulate matter.

A supplier that can provide a validated paricalcitol-compatible lipid vehicle, cosolvent system or softgel shell may capture value without marketing a finished drug. Excipient suppliers can pursue dual sourcing, formulation-development partnerships and technical-service contracts with generic manufacturers.

What licensing deals and partnership opportunities exist?

The most credible partnership models are formulation and supply agreements rather than licenses to the active molecule.

Attractive deal structures

1. Excipient supplier plus generic manufacturer
   The supplier provides a proprietary solubilizer, lipid system or capsule shell supported by stability and compatibility data.

2. Contract development and manufacturing organization partnership
   A CDMO develops and manufactures a ready-to-use injectable or low-solvent presentation.

3. Dialysis-provider supply agreement
   A manufacturer contracts directly with dialysis networks on price, availability and workflow benefits.

4. 505(b)(2) development license
   A sponsor licenses a formulation or delivery platform and pursues a differentiated paricalcitol product.

5. Regional commercialization partnership
   A manufacturer combines a formulation platform with local registration, packaging and distribution capabilities.

The strongest licensing assets will have platform potential beyond paricalcitol. A technology applicable to other poorly water-soluble injectable drugs is more valuable than a single-product excipient change.

How strong is the commercial opportunity for paricalcitol excipients?

The opportunity is moderate for commodity excipients and stronger for specialized formulation systems.

Opportunity	Market attractiveness	Main reason
Standard ethanol or propylene glycol supply	Low	Broad competition and limited differentiation
Pharmaceutical-grade lipid vehicle	Moderate	Supports oral solubility and dose uniformity
Low-solvent injectable platform	High	Potential handling and tolerability benefits
Ready-to-use packaging	Moderate to high	Addresses dialysis workflow and waste
Gelatin-free capsule shell	Moderate	Supports niche purchasing and patient preferences
Novel modified-release formulation	Uncertain	Requires clinical differentiation
Manufacturing analytics and process controls	Moderate	Can reduce batch failure and improve yield
Combination product with mineral-management therapy	Uncertain	Clinical and regulatory complexity

Revenue exposure is likely concentrated in mature generic pricing, so cost savings and supply reliability are central to value creation. A premium excipient strategy must produce measurable benefits in administration, stability, patient tolerability or manufacturing economics.

What generic launch scenarios exist for paricalcitol?

Scenario 1: Price-led generic entry

A manufacturer launches standard-equivalent capsules or injection. The product competes primarily on price and supply. Margins compress quickly, and the main advantage is manufacturing scale.

Scenario 2: Reliability-led entry

The manufacturer differentiates through redundant API and excipient supply, strong shortage performance and dependable delivery to dialysis providers. This can support preferred contracting even without a novel dosage form.

Scenario 3: Formulation-led entry

A sponsor launches a lower-solvent injection, prefilled syringe or improved oral formulation. The product may support higher pricing if the FDA label and clinical data establish a meaningful benefit.

Scenario 4: Workflow-led entry

The product is packaged to minimize preparation, dosing errors and unused product. The commercial buyer is the dialysis organization or hospital system rather than the individual patient.

What geographic opportunities exist?

The United States is a mature generic market with strong emphasis on ANDA compliance, contracting and supply reliability. European markets may offer opportunities through decentralized or national procedures, but pricing controls can limit returns. Emerging markets may favor lower-cost oral products, local packaging and stable room-temperature supply.

Regional excipient opportunities include:

• Vegetarian capsule systems for markets with gelatin restrictions.
• Preservative-free injections for hospital tenders.
• Local fill-finish partnerships.
• Smaller pack sizes for markets with lower treatment volumes.
• Temperature-stable formulations where cold-chain infrastructure is limited.

The active ingredient is not a biologic, so biosimilar development is not relevant. Regulatory strategy centers on generic equivalence, formulation innovation and manufacturing compliance.

Key Takeaways

• Paricalcitol is a mature generic vitamin D analog with limited remaining value in core-molecule exclusivity.
• Oral products rely on lipid vehicles, ethanol, propylene glycol and softgel capsule components.
• Injectable products rely on ethanol and propylene glycol as solubilizing excipients.
• Low-solvent injections, ready-to-use presentations and low-waste packaging are the most credible differentiated opportunities.
• Microgram-level dose uniformity is a central oral manufacturing challenge.
• Excipient changes alone are unlikely to command premium pricing without a clinical, handling or manufacturing benefit.
• The strongest intellectual-property position may come from formulation, packaging and manufacturing-process claims.
• Biosimilar risk does not apply; generic and 505(b)(2) pathways control market entry.
• Dialysis-provider contracting and supply reliability may be more important than retail brand recognition.
• Excipient suppliers with platform technologies applicable to other poorly soluble drugs have greater licensing potential than suppliers offering commodity materials.

FAQs

Can paricalcitol be formulated without propylene glycol?

Potentially, but the replacement system must maintain solubility, stability, sterility and acceptable administration characteristics. Cyclodextrins, surfactants, polymers and lipid systems are possible development routes.

Are paricalcitol capsules oil-based?

Yes. The reference capsule formulation uses a lipid vehicle, including medium-chain triglycerides, with cosolvents that support dissolution and content uniformity. [1]

Is paricalcitol a biologic requiring biosimilar approval?

No. Paricalcitol is a small-molecule drug. Generic approval generally proceeds through the ANDA pathway, while materially differentiated formulations may use the 505(b)(2) pathway.

What is the best excipient opportunity for a paricalcitol supplier?

A validated low-solvent injectable system or a high-uniformity lipid formulation is more commercially defensible than supplying standard ethanol, propylene glycol or gelatin alone.

Can a new paricalcitol formulation obtain patent protection?

Yes, potentially. Patentable subject matter may include specific excipient ratios, concentrations, stability profiles, delivery systems, manufacturing methods or treatment methods. Patentability depends on novelty, nonobviousness, written description and claim scope.

References

1. U.S. Food and Drug Administration. (2023). Zemplar (paricalcitol) capsules and injection prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA): Generics. FDA.

3. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

6. Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59.